Marcus R. Pereira

Marcus R. Pereira

Auto-generated profile, based on publicly available information

Marcus R. Pereira

Division of Infectious Diseases Department of Medicine Columbia University Irving Medical Center New York City New York USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
MPMarcus R. Pereira
Marcus R. Pereira
SMSumit Mohan
Sumit Mohan
DCDavid J. Cohen
David J. Cohen
SHSyed A. Husain
Syed A. Husain
GDGeoffrey Dube
Geoffrey Dube
EVElizabeth C. Verna
Elizabeth C. Verna
Solid organ transplant recipients may be at a high risk for SARS-CoV-2 infection and poor associated outcomes. We herein report our initial experience with solid organ transplant recipients with SARS-CoV-2 infection at two centers during the first 3 weeks of the outbreak in New York City. Baseline characteristics, clinical presentation, antiviral and immunosuppressive management were compared between patients with mild/moderate and severe disease (defined as ICU admission, intubation or death). Ninety patients were analyzed with a median age of 57 years. Forty-six were kidney recipients, 17 lung, 13 liver, 9 heart, and 5 dual-organ transplants. The most common presenting symptoms were fever (70%), cough (59%), and dyspnea (43%). Twenty-two (24%) had mild, 41 (46%) moderate, and 27 (30%) severe disease. Among the 68 hospitalized patients, 12% required non-rebreather and 35% required intubation. 91% received hydroxychloroquine, 66% azithromycin, 3% remdesivir, 21% tocilizumab, and 24% bolus steroids. Sixteen patients died (18% overall, 24% of hospitalized, 52% of ICU) and 37 (54%) were discharged. In this initial cohort, transplant recipients with COVID-19 appear to have more severe outcomes, although testing limitations likely led to undercounting of mild/asymptomatic cases. As this outbreak unfolds, COVID-19 has the potential to severely impact solid organ transplant recipients.

1 July 2015 in Liver Transplantation
Verified
Journal Article
Open access
PDF file
MPMarcus R. Pereira
Marcus R. Pereira
BSBrendan F. Scully
Brendan F. Scully
SPStephanie M. Pouch
Stephanie M. Pouch
AUAnne‐Catrin Uhlemann
Anne‐Catrin Uhlemann
SGStella Goudie
Stella Goudie
EVElizabeth C. Verna
Elizabeth C. Verna
Carbapenem‐resistant Klebsiella pneumoniae (CRKP) infection is increasing in incidence and is associated with increased mortality in liver transplantation (LT) recipients. We performed a retrospective cohort study of all patients transplanted between January 2010 and January 2013 to identify the incidence and risk factors for post‐LT CRKP infection and evaluate the impact of this infection on outcomes in a CRKP‐endemic area. We studied 304 recipients, of whom 20 (6.6%) developed CRKP and 36 (11.8%) carbapenem‐susceptible Klebsiella pneumoniae (CSKP) infections in the year following LT. Among the 20 recipients with post‐LT CRKP infection, 8 (40%) were infected in ≥ 2 sites; 13 (65%) had surgical site–intra‐abdominal infections; 12 (60%) had pneumonia; and 3 (15%) had a urinary tract infection. There were 6 patients with a CRKP infection before LT, 5 of whom developed a CRKP infection after LT. Significant risk factors for post‐LT CRKP infection in multivariate analysis included laboratory Model for End‐Stage Liver Disease at LT (odds ratio [OR], 1.07; P = 0.001), hepatocellular carcinoma (OR, 3.19; P = 0.02), Roux‐en‐Y biliary choledochojejunostomy (OR, 3.15; P = 0.04), and bile leak (OR, 5.89; P = 0.001). One‐year estimated patient survival was 55% (95% confidence interval, 31%‐73%), 72% (55%‐84%), and 93% (89%‐96%), for patients with CRKP, CSKP, and no Klebsiella pneumoniae infection, respectively. In multivariate analysis, CRKP (hazard ratio [HR], 6.92; P < 0.001) and CSKP infections (CSKP, HR, 3.84; P < 0.001), as well as bile leak (HR, 2.10; P = 0.03) were the strongest predictors of post‐LT mortality. In an endemic area, post‐LT CRKP infection is common, occurring in 6.6% of recipients, and is strongly associated with post‐LT mortality. Improved strategies for screening and prevention of CRKP infection are urgently needed. Liver Transpl 21:1511‐1519, 2015. © 2015 AASLD.

21 March 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
DSDavid M. Salerno
David M. Salerno
DJDouglas L. Jennings
Douglas L. Jennings
NLNicholas W. Lange
Nicholas W. Lange
DKDanielle (Bley) Kovac
Danielle (Bley) Kovac
TSTara Shertel
Tara Shertel
MPMarcus R. Pereira
Marcus R. Pereira
Nirmatrelvir/ritonavir (NR) use has not yet been described in solid organ transplant recipients (SOTRs) with mild COVID‐19. The objective was to evaluate outcomes among SOTR and describe the drug–drug interaction of NR. This is an IRB‐approved, retrospective study of all adult SOTR on a calcineurin inhibitor (CNI) or mammalian target of rapamycin inhibitor who were prescribed NR between December 28, 2021 and January 6, 2022. A total of 25 adult SOTR were included (n = 21 tacrolimus, n = 4 cyclosporine, n = 3 everolimus, n = 1 sirolimus). All patients were instructed to follow the following standardized protocol during treatment with 5 days of NR: hold tacrolimus or mTOR inhibitor or reduce cyclosporine dose to 20% of baseline daily dose. Four patients (16%) were hospitalized by day 30; one for infectious diarrhea and three for symptoms related to COVID‐19. No patients died within 30 days of receipt of NR. Median tacrolimus level pre‐ and post‐NR were 7.4 ng/ml (IQR, 6.6–8.6) and 5.2 (IQR, 3.6–8.7), respectively. Four patients experienced a supratherapeutic tacrolimus concentration after restarting tacrolimus post‐NR. Our results show the clinically significant interaction between NR and immunosuppressive agents can be reasonably managed with a standardized dosing protocol. Prescribers should carefully re‐introduce CNI after the NR course is complete.

2 April 2021 in Science Immunology
Verified
Journal Article
Closed access
PDF file
TYTae Jin Yun
Tae Jin Yun
SISuzu Igarashi
Suzu Igarashi
HZHaoquan Zhao
Haoquan Zhao
OPOriana A. Perez
Oriana A. Perez
MPMarcus R. Pereira
Marcus R. Pereira
BRBoris Reizis
Boris Reizis
PDCs recognize cells infected with human cytomegalovirus and respond with a unique prolonged activation program.

11 January 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
NLNicholas W. Lange
Nicholas W. Lange
DSDavid M. Salerno
David M. Salerno
DJDouglas L. Jennings
Douglas L. Jennings
JCJason Choe
Jason Choe
JHJessica Hedvat
Jessica Hedvat
MPMarcus R. Pereira
Marcus R. Pereira

9 August 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
MAMeghan Aversa
Meghan Aversa
LBLuke Benvenuto
Luke Benvenuto
MAMichaela Anderson
Michaela Anderson
LSLori Shah
Lori Shah
HRHilary Robbins
Hilary Robbins
TPThe Columbia University Lung Transplant Program
The Columbia University Lung Transplant Program
There are limited data describing COVID‐19 in lung transplant recipients. We performed a single center, retrospective case series study of lung transplant patients followed by the Columbia Lung Transplant program who tested positive for SARS‐CoV‐2 between March 19‐May 19, 2020. 32 lung transplant patients developed mild (16%), moderate (44%), or severe (41%) COVID‐19. The median age of patients was 65 years, and the median time from lung transplant was 5.6 years. Symptoms included cough (66%), dyspnea (50%), fever (47%), and gastrointestinal upset (44%). Patients received hydroxychloroquine (84%), azithromycin (75%), augmented steroids (44%), tocilizumab (19%), and remdesivir (9%). 11 patients (34%) died at a median time of 14 days from admission. Complications during admission included: acute kidney injury (63%), transaminitis (31%), shock (31%), acute respiratory distress syndrome (25%), neurological events (25%), arrhythmias (22%), and venous thromboembolism (9%). Compared to patients with moderate COVID‐19, patients with severe COVID‐19 had higher peak white blood cell counts (15.8 vs. 7 x 103/uL, p=0.019), C‐reactive protein (198 vs. 107 mg/L, p=0.010) and D‐dimer (8.6 vs. 2.1 ug/mL, p=0.004) levels, and lower nadir lymphocyte counts (0.09 vs. 0.4x 103/uL, p=0.006). COVID‐19 is associated with severe illness and a high mortality rate in lung transplant recipients.